Literature DB >> 23142922

[Results of a randomized phase III study on treatment of recurrent glioblastoma: NovoTTF-100A versus chemotherapy].

C Nieder1.   

Abstract

Entities:  

Year:  2013        PMID： 23142922     DOI： 10.1007/s00066-012-0251-8

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  7 in total

1.  Irradiation and bevacizumab in high-grade glioma retreatment settings.

Authors:  Maximilian Niyazi; Ute Ganswindt; Silke Birgit Schwarz; Friedrich-Wilhelm Kreth; Jörg-Christian Tonn; Julia Geisler; Christian la Fougère; Lorenz Ertl; Jennifer Linn; Axel Siefert; Claus Belka
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-27       Impact factor: 7.038

2.  A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma.

Authors:  Michael D Prados; S Clifford Schold; Howard A Fine; Kurt Jaeckle; Fred Hochberg; Laszlo Mechtler; Michael R Fetell; Surasak Phuphanich; Lynn Feun; Todd J Janus; Kathleen Ford; William Graney
Journal:  Neuro Oncol       Date:  2003-04       Impact factor: 12.300

3.  Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma.

Authors:  G Minniti; V Armosini; M Salvati; G Lanzetta; P Caporello; M Mei; M F Osti; R Enrici Maurizi
Journal:  J Neurooncol       Date:  2010-11-05       Impact factor: 4.130

4.  NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.

Authors:  Roger Stupp; Eric T Wong; Andrew A Kanner; David Steinberg; Herbert Engelhard; Volkmar Heidecke; Eilon D Kirson; Sophie Taillibert; Frank Liebermann; Vladimir Dbalý; Zvi Ram; J Lee Villano; Nikolai Rainov; Uri Weinberg; David Schiff; Lara Kunschner; Jeffrey Raizer; Jerome Honnorat; Andrew Sloan; Mark Malkin; Joseph C Landolfi; Franz Payer; Maximilian Mehdorn; Robert J Weil; Susan C Pannullo; Manfred Westphal; Martin Smrcka; Lawrence Chin; Herwig Kostron; Silvia Hofer; Jeffrey Bruce; Rees Cosgrove; Nina Paleologous; Yoram Palti; Philip H Gutin
Journal:  Eur J Cancer       Date:  2012-05-18       Impact factor: 9.162

5.  Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.

Authors:  Wolfgang Wick; Vinay K Puduvalli; Marc C Chamberlain; Martin J van den Bent; Antoine F Carpentier; Lawrence M Cher; Warren Mason; Michael Weller; Shengyan Hong; Luna Musib; Astra M Liepa; Donald E Thornton; Howard A Fine
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

6.  Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.

Authors:  Martin J van den Bent; Alba A Brandes; Roy Rampling; Mathilde C M Kouwenhoven; Johan M Kros; Antoine F Carpentier; Paul M Clement; Marc Frenay; Mario Campone; Jean-Francois Baurain; Jean-Paul Armand; Martin J B Taphoorn; Alicia Tosoni; Heidemarie Kletzl; Barbara Klughammer; Denis Lacombe; Thierry Gorlia
Journal:  J Clin Oncol       Date:  2009-02-09       Impact factor: 44.544

7.  Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide.

Authors:  Gregor Dresemann; Michael Weller; Mark A Rosenthal; Ulrich Wedding; Wolfgang Wagner; Erik Engel; Bernhard Heinrich; Regine Mayer-Steinacker; Anders Karup-Hansen; Oystein Fluge; Anna Nowak; Maximilian Mehdorn; Eberhard Schleyer; Dietmar Krex; Ian N Olver; Joachim P Steinbach; Christian Hosius; Christian Sieder; Greg Sorenson; Richard Parker; Zariana Nikolova
Journal:  J Neurooncol       Date:  2009-08-18       Impact factor: 4.130
  7 in total
  1 in total

1.  In Vitro and in Vivo Study of the Effect of Osteogenic Pulsed Electromagnetic Fields on Breast and Lung Cancer Cells.

Authors:  Mike Y Chen; Jing Li; Nianli Zhang; Erik I Waldorff; James T Ryaby; Philip Fedor; Yongsheng Jia; Yujun Wang
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.